
Sign up to save your podcasts
Or


Do you want to know how to approach Pharma?
Do you want to learn what information is needed to partner a life science project with Pharma?
And how long the process takes?
Then this podcast is for you.
Listen to the expertise of Natalia Novac, Director of Emerging Technologies and Innovation, Eli Lilly.
Natalia has profound experience in strategy, corporate, and business development. She had leading roles at Merck and now Eli Lilly.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Natalia Novac (https://www.linkedin.com/in/natalia-novac-a3aa7131/)
Companies:
Eli Lilly (https://www.linkedin.com/company/eli-lilly-and-company/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
In light of the pandemic, the Life Science Industry is changing. One of the positive developments: The industry is moving faster. The necessity of developing diagnostics, therapeutics, and vaccines against this novel viral threat quickly generates a steep learning curve for all of us.
In this episode, I am talking with Peter Llewellyn-Davies, CEO of Apeiron Biologics, how he and his team have set up a clinical phase 2 trial and a 40 million Euro financing round in less than eight weeks.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Peter Llewellyn-Davies (https://www.linkedin.com/in/peterld/)
Companies:
Apeiron Biologics (https://www.linkedin.com/company/apeiron-biologics/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Be part of our Network:
Subscribe here: https://mailchi.mp/e2467061ef75/lsg2g
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Since the beginning of the SARS-CoV-2 Pandemic, more and more people got interested in the Life Science Industry.
Scientists worldwide have worked together for decades and centuries to solve the world's most severe health problems.
In the last decades, a unique Eco-System of start-ups, investors, industrial partners, and public funding organizations evolved out of this search for finding cures against the world's most complex diseases.
In this episode, you will hear:
How important is building strong relationships?
How does this Life Science Value Eco System function in 2020?
How do companies, investors, and Start-Ups interact with each other?
What roles does the player have?
How do investors life look like?
And how do Start-Ups approach investors?
Speaker:
Bruno Montanari (https://www.linkedin.com/in/bruno-montanari-882559/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Seroba Life Sciences (https://www.linkedin.com/company/serobalifesciences/)
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Two attempts to secure investment fell through. The founders started YUMAB anyway.
Then came another lesson: the researchers who wanted their technology often lacked the budget to buy it. A major pharma client later disappeared for a year after changing strategy. Good science alone would not keep the company alive.
In this episode of Beginner’s Mind, Thomas Schirrmann joins Christian Soschner to explain how he moved from academic research into biotech entrepreneurship—and helped build YUMAB into a 25-person antibody discovery company by the time of this recording.
We explore two very different business models: earning revenue through contract research and raising investment to develop therapeutic drugs. Each demands different decisions about customers, capital, risk, and control.
Thomas explains why winning a first contract can take a year, why scientific founders need to learn business development, and why the gap between a university discovery and a clinical candidate remains so difficult to finance.
Recorded in August 2020. The discussion of COVID-19 antibody development and CORAT Therapeutics reflects the projects and expectations at that time.
WHAT YOU WILL LEARN
• How YUMAB got started after two unsuccessful attempts to secure investment.
• Why a promising technology still needs customers with purchasing power.
• How repeated meetings build the trust needed to win biotech contracts.
• What separates a research finding from an asset a pharma company will license.
• How contract research and drug development differ in funding needs and founder autonomy.
• Why delaying a difficult decision can become a founder’s most expensive mistake.
CHAPTERS
(00:00:00) Introduction: two ways to build a life science business
(00:01:16) From academic scientist to biotech entrepreneur
(00:04:45) Starting YUMAB after funding attempts fell through
(00:06:33) Finding customers and changing the business plan
(00:12:31) Why technology alone does not win contracts
(00:17:57) Learning to fail—and knowing when to stop a project
(00:21:04) Why academic expectations and commercial valuations collide
(00:25:00) Is the market always right?
(00:27:43) Learning from customers instead of waiting for perfection
(00:30:06) Building the bridge between universities and pharma
(00:34:28) Founder networks and support for early research
(00:37:53) Why patents and publications are not enough
(00:45:59) The funding gap before clinical development
(00:47:40) Academic expertise and the origins of CORAT Therapeutics
(00:53:40) Why a small biotech needs millions in funding
(00:55:14) Developing a COVID-19 antibody: the 2020 plan
(00:57:13) Finding the right leadership and preparing the next funding step
(00:59:57) Scientific purpose and the motivation to keep going
(01:02:56) The personal demands of building a biotech company
(01:08:13) Why waiting too long to decide is costly
(01:09:46) Investor trust, founder freedom, and decision-making
(01:17:07) Advice to a younger self: make your own decisions
(01:20:26) Closing thoughts
MORE FROM BEGINNER’S MIND
Ideas and conversations for people building companies:
https://lsg2g.substack.com/
Follow Beginner’s Mind on your podcast platform, and share this episode with a scientist or founder turning research into a business.
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
How is it to start a company from scratch, found it and fund it in the US, and get customers like the US Air Force and the Department of Defence.
In this episode, you will hear how Jessica Walsh, Founder, and CEO of RxBandz, a successful woman in life science, did it.
In this episode, listen to Jessica’s stories about how to get into life science out of necessity, how it is to find the right team and develop the team and the project at the same time.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Jessica Walsh (https://www.linkedin.com/in/jessica-walsh-3025807/)
Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
RxBandz (https://www.linkedin.com/company/rx-bandz/)
Do you want to learn more about life science?
Subscribe to our newsletter: https://mailchi.mp/e2467061ef75/lsg2g
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
We are the average of the five people we spent the most time with. Or are we the opposite?
Listen in this podcast episode how Daria Tataj sees it. Daria is THE number one networking expert in Europe.
Daria Tataj is a researcher, Ph.D., keynote speaker, author, and world expert on innovation networks.
After having reached more than 30.000 decision-makers around the world through her work helping companies, governments, and cities to foster innovation through the strategic use of networks,
Daria has now decided to share her knowledge with you in one Program, the Network Thinking Training.
She is also one of the founding board members of the European Institute of Innovation & Technology (https://eit.europa.eu/)
Do you want to get in touch with Daria?
Join her next networking webinar: https://tatajinnovation.com/forhealth/
Special Offer:
As a subscriber to this podcast you get a EUR 100,- discount. Passcode: LSG2G
Partner and member get a 46% discount.
Become a member and send a mail to [email protected] for further information
Book:
Get Darias book at Amazon: https://amzn.to/2YJtMy4
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Daria Tataj (https://www.linkedin.com/in/dariatataj/)
Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Tataj Innovation (https://tatajinnovation.com/)
Do you want to learn more about life science?
Become a member of the LSG2G Network.
Join today: https://www.lifescienceget2gether.com/registration-membersclub/
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Life sciences touch all of our lives—but few people truly understand the enormous challenges behind bringing an idea from the lab to the marketplace. The journey from university research to a real-world product is filled with risks, obstacles, and breakthroughs.
Since the outbreak of SARS-CoV-2, interest in life science innovation and investment has skyrocketed. But what does it actually take to succeed in this field? How do investors evaluate opportunities? And is this industry the right space for business angels looking to get involved?
In this episode, I sit down with entrepreneurs and investors from the LSG2G network to unpack these questions. Together with the keynote speaker and panelists, we explore the mechanics of life science investing, the mindset of top investors, and what it really takes to turn cutting-edge science into impactful products.
Speaker:
Andreas Grassauer (https://www.linkedin.com/in/andreas-grassauer-048843b2/)
Astrid Woollard (https://www.linkedin.com/in/astridwoollard/)
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Christopher de Souza (https://www.linkedin.com/in/cdesouza1/)
Henriette Lininger (https://www.linkedin.com/in/henriette-lininger-90759615/)
Sara Núñez-Garcia (https://www.linkedin.com/in/sara-n%C3%BA%C3%B1ez-garcia-phd-mba-00141a3/)
Walter Stockinger (https://www.linkedin.com/in/walter-stockinger-dr-13b1a4b/)
Companies:
Broadview Ventures (https://www.linkedin.com/company/broadview-ventures-inc/about/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Hadean Ventures (https://www.linkedin.com/company/hadean-ventures/)
LSG2G (https://www.lifescienceget2gether.com/)
Marinomed (https://www.linkedin.com/company/marinomed-biotech-ag)
Roivant Sciences (https://roivant.com/)
Scytale Ventures (https://www.linkedin.com/company/scytale-ventures/)
Vienna Stock Exchange (https://www.linkedin.com/company/wiener-borse-ag/)
Do you want to learn more about life science?
Join exclusive future webinars and member-only events: Become a member of the LSG2G Network.
Join today: https://www.lifescienceget2gether.com/registration-membersclub/
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
The current pandemic shines a light on deep tech companies. Especially in life science. Did you ask yourself the question: What is necessary to bring a scientific idea from universities into companies and ultimately onto the market?
In this episode, I am talking with Klara Brandstätter and Jasmin Gungör. They are responsible for training, financing, and connecting deep-tech scientists.
What exactly they are doing, you will hear in this episode.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Jasmin Güngör (https://www.linkedin.com/in/jasmin-g%C3%BCng%C3%B6r-62111959/)
Klara Brandstätter (https://www.linkedin.com/in/klara-brandst%C3%A4tter-b6029491/)
Companies:
CS Life Science Invest (https://www.cslifescienceinvest.com/)
IECT Summer School (https://www.iect.at/en/i-e-c-t-summer-school-on-entrepreneurship-en/)
Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get an individual "member only" invitation and will have a chance to talk with the speakers directly during the recording. The questions will be featured in the podcast.
Do you like this idea? Join today: https://www.lifescienceget2gether.com/registration-membersclub/
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
How to bring scientific life science ideas to patients?
Three key components are needed:
1. World-class science
2. World-class development team
3. Massive public and private funding
In this episode, I am talking with Michael Browne and Kimberly Cornfield on how to solve these three problems.
Reach out to Kimberly and Michael if you want to access their top-notch science networks within Crowdhelix and UCL.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Kimberly Cornfield (https://www.linkedin.com/in/kimberly-cornfield-55383136/)
Michael Browne (https://www.linkedin.com/in/michael-browne-frsa-5a616138/)
Companies:
Crowdhelix (https://crowdhelix.com/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
UCL (https://www.ucl.ac.uk/)
Do you enjoy the podcast?
Become a member of the LSG2G Network and join the recording. You will get a special "member only" invitation. You will have the unique opportunity to talk with the speakers directly in the Q&A - and you will get featured in the podcast episode.
Join the community: https://lsg2g.substack.com/subscribe
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
The current pandemic SARS Cov 2 is shining a light on vaccine development. Since December 2019, the novel coronavirus is known amongst scientists. The virus is highly contagious. As a first measure, many governments all over the world have ordered a complete lockdown of the countries.
Some politicians make reverting life back to normal dependent on the existence of medication and/or vaccine. How long does it take to develop a vaccine against this novel coronavirus?
In this episode, the vaccine development expert Erich Tauber, CEO, and founder of Themis Bioscience, explains what it takes to develop a novel vaccine and also gives an outlook on the timeline.
It was a huge pleasure to be accompanied by Elisabeth Pfneisl, Addendum.org, during the recording of this interview.
Speaker:
Christian Soschner (https://www.linkedin.com/in/christiansoschner/)
Elisabeth Pfneisl (https://www.linkedin.com/in/elisabeth-pfneisl-81095163/)
Erich Tauber (https://www.linkedin.com/in/erich-tauber-0ba8a111/)
Companies:
Addendum.org (https://www.addendum.org/)
CS Life Science Invest (https://www.cslifescienceinvest.com/)
Themis BioScience (https://themisbio.com/)
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link